Business, energy, technology, markets and global industry news from Business News Today
PharmaDeviceNews
Representative image: A clinician reviews pancreatic cancer imaging and oncology trial data as Phanes Therapeutics’ spevatamig Phase 2 results highlight the growing role of bispecific antibody research in first-line metastatic pancreatic ductal adenocarcinoma treatment.
Pharma & Biotech

Alterome Therapeutics schedules first Phase 1 clinical data presentation for pan-KRAS inhibitor ALTA3263

Alterome Therapeutics will reveal first ALTA3263 Phase 1 data in November, testing the safety and early activity of its oral pan-KRAS inhibitor.

Read More
Clinical researchers review Phase 3 data for plozasiran after Arrowhead Pharmaceuticals reported substantial triglyceride reductions and fewer acute pancreatitis events in the SHASTA-3 and SHASTA-4 studies. Representative image.
Pharma & Biotech

Arrowhead Pharmaceuticals secures NHS funding recommendation for REDEMPLO in familial chylomicronaemia syndrome

REDEMPLO gains NHS backing for genetically confirmed FCS in England and Wales, following strong triglyceride reductions in the PALISADE trial.

Read More
Representative image illustrating lupus drug research as Beeline Medicines reports promising Phase 2 afimetoran results, highlighting its potential as an oral treatment for systemic lupus erythematosus.
Pharma & Biotech

Afimetoran Phase 2 trial delivers significant lupus improvement as Beeline Medicines eyes pivotal studies

Explore Beeline Medicines' Phase 2 afimetoran lupus results, showing a 30-point response advantage and promising potential for an oral therapy.

Read More
Representative image of babesiosis research and tick-borne infection testing as 60 Degrees Pharmaceuticals reports promising parasite clearance results in patients with relapsing babesiosis treated with tafenoquine-based combination therapy.
Pharma & Biotech

Tafenoquine combinations show promising parasite clearance in immunocompromised patients with babesiosis

60 Degrees Pharmaceuticals reports negative Babesia PCR tests in five patients receiving tafenoquine combinations, with FDA discussions planned.

Read More
Representative image illustrating brain cancer research and targeted radiotherapy as Cerenome prepares to unveil new REYOBIQ clinical trial data evaluating multidose treatment for leptomeningeal metastases, a challenging complication of advanced cancer.
Pharma & Biotech

REYOBIQ brain cancer trial: Cerenome advances targeted radiotherapy ahead of Phase 2 plans

Explore Cerenome's upcoming REYOBIQ brain cancer trial data and what its multidose study could mean for leptomeningeal metastases treatment.

Read More
Representative image of metastatic prostate cancer research as Syncromune’s investigational SYNC-T immunotherapy demonstrates 80% two-year survival and durable complete responses in an early Phase 1 clinical trial.
Pharma & Biotech

SYNC-T prostate cancer treatment shows encouraging long-term survival as LEGION-100 trial expands

Syncromune's SYNC-T therapy shows 80% two-year survival in a Phase 1 metastatic prostate cancer trial. Explore results and Phase 2a plans.

Read More
Representative image of asthma and atopic dermatitis research as Aclaris Therapeutics’ investigational antibody ATI-052 demonstrates promising Phase 1b clinical results, reducing airway inflammation by 59% and improving eczema severity by 58%.
Pharma & Biotech

Could ATI-052 offer a new approach to asthma and eczema? Phase 1b findings support further testing

Aclaris Therapeutics' ATI-052 shows promising Phase 1b asthma and eczema results. Explore the clinical findings and upcoming Phase 2b plans.

Read More
Pharma & Biotech

Tremont AI partners with AstraZeneca to develop AI models for preclinical drug safety assessment

Tremont AI partners with AstraZeneca to develop preclinical safety models, targeting rare toxicity signals and more consistent pathology assessment.

Read More
Representative image: Dermatology examination of raised skin welts illustrates Novartis’ FDA approval of Rhapsido for symptomatic dermographism in adults uncontrolled on antihistamines.
Pharma & Biotech

Array Skin Therapy opens first Houston clinic to expand narrowband UVB treatment access

Array Skin Therapy opens its first Houston clinic, expanding narrowband UVB treatment access for psoriasis, vitiligo and eczema patients.

Read More
Laminar Pharma’s LAM561 Phase 2b/3 glioblastoma trial has completed its final patient visit, moving the investigational therapy toward a pivotal overall survival readout expected in 2027. Representative image.
Pharma & Biotech

Alpheus Medical reports early LDH biomarker findings from 15-patient glioblastoma study

Alpheus Medical reports LDH biomarker findings in 15 glioblastoma patients. The early signal could aid MRI interpretation but needs validation.

Read More